Back to top
more

Meridian Bioscience Inc. (VIVO)

(Delayed Data from NSDQ)

$11.51 USD

11.51
1,168,817

-0.48 (-4.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 1.56% and 1.72%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Beats Q4 Earnings Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 6.90% and 6.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VAREX IMAGING (VREX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of 52.38% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ascend Wellness Holdings, Inc. (AAWH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -125% and 6.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 0% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 43.75% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Computer Programs and Systems (CPSI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Computer Programs and Systems (CPSI) and Meridian Bioscience (VIVO) have performed compared to their sector so far this year.

Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)

by Zacks Equity Research

Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

What Awaits Meridian Bioscience (VIVO) This Earnings Season?

by Zacks Equity Research

Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

McKesson (MCK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.